AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31094331 — intervention group
Group type: COMPARATOR
Intervention: Unguided i-RFCBT
Number of subjects: 235
Study 28318984 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus neurovascular thrombectomy (Solitaire FR)
Number of subjects: 206
Study 28318984 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 206
Study 25603459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d)
Number of subjects: 428
Study 25603459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study 24417601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 488
Study 24417601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 488
Study 24417601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and Sertraline (COMB)
Number of subjects: 488
Study 24417601 — intervention group
Group type: COMPARATOR
Intervention: Medication management with pill placebo (PBO)
Number of subjects: 488
Study 22935042 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra protein (33 g whey protein/day)
Number of subjects: 24
Study 22935042 — intervention group
Group type: COMPARATOR
Intervention: Fast-food meal (1350 kcal, 41 g protein)
Number of subjects: 24
Study 19324370 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant cough
Number of subjects: 238
Study 19324370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nose symptoms
Number of subjects: 238
Study 19324370 — intervention group
Group type: EXPERIMENTAL
Intervention: Insignificant cough
Number of subjects: 238
Study 17543376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 18 months
Number of subjects: 56
Study 17543376 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 18 months
Number of subjects: 56
Study 15389420 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief screener using scales from the National Cancer Institute (NCI) Percent Energy from Fat Screener and 5‐A‐Day trials
Number of subjects: 203
Study 11475558 — intervention group
Group type: EXPERIMENTAL
Intervention: BALF-ACE activity in patients with sarcoidosis
Number of subjects: 40
Study 11475558 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum antibodies against 38 kDa
Number of subjects: 40
Study 11475558 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ACE activity
Number of subjects: 40
Study 11475558 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CEA concentration
Number of subjects: 40
Study 11475558 — intervention group
Group type: COMPARATOR
Intervention: BALF-ACE activity
Number of subjects: 40
Study 11475558 — intervention group
Group type: COMPARATOR
Intervention: Serum antibodies against 38 kDa and ACE activity
Number of subjects: 40
Study 9806257 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg per day Org OD 14 (tibolone) for 3 months
Number of subjects: 18
Study 9806257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multi-vitamin pill) for 3 months
Number of subjects: 18
Study 9806257 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone treatment
Number of subjects: 18
Study 7699827 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian approach (Group P)
Number of subjects: 71
Study 7699827 — intervention group
Group type: COMPARATOR
Intervention: Median approach (Group M)
Number of subjects: 71
Study 2529112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (0.2 mg/kg)
Number of subjects: 50
Study 2529112 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial (0.21 mg/kg) plus intravenous (0.09 mg/kg) therapy
Number of subjects: 50
Study 2529112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 767366 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group - patients recalled once every second week for professional tooth cleaning
Number of subjects: 24
Study 767366 — intervention group
Group type: COMPARATOR
Intervention: Control group - patients recalled once every 12 months for prophylaxis
Number of subjects: 24
Study 31231803 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-child race/ethnicity matching
Number of subjects: 5200
Study 31231803 — intervention group
Group type: COMPARATOR
Intervention: Teacher-child mismatch in low-diversity classrooms
Number of subjects: 5200
Study 31231803 — intervention group
Group type: COMPARATOR
Intervention: Teacher-child mismatch in high-diversity classrooms
Number of subjects: 5200
Study 31556787 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 45
Study 31556787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 45
Study 31556787 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 45
Study 28814455 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care supplemented by 4 virtual visits via video conferencing
Number of subjects: 195
Study 28814455 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 195
Study 28814455 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual house calls
Number of subjects: 195
Study 25907250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose haloperidol
Number of subjects: 455
Study 25907250 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 455
Study 25907250 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 455
Study 25907250 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 455
Study 25907250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 455
Study 24267860 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-cessation support delivered by text message
Number of subjects: 25
Study 21546309 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based voluntary counselling and testing (CBVCT)
Number of subjects: 6250
Study 21546309 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic-based voluntary counselling and testing (SVCT)
Number of subjects: 6250
Study 19817193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizhen
Number of subjects: 320
Study 19817193 — intervention group
Group type: COMPARATOR
Intervention: Massage (Control)
Number of subjects: 320
Study 18632013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions and medication
Number of subjects: 0
Study 18632013 — intervention group
Group type: COMPARATOR
Intervention: Cost-utility analyses
Number of subjects: 0
Study 15119583 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus (OP) with 15 s etching time
Number of subjects: 32
Study 15119583 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (SB) with 15 s etching time
Number of subjects: 32
Study 15119583 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus (OP) with 30 s etching time
Number of subjects: 32
Study 15119583 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (SB) with 30 s etching time
Number of subjects: 32
Study 15119583 — intervention group
Group type: COMPARATOR
Intervention: Single Bond (SB)
Number of subjects: 32
Study 11915638 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate bioadhesive
Number of subjects: 0
Study 9728851 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane alone
Number of subjects: 100
Study 9728851 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-dose esmolol (250 microg x kg(‐1) x min(‐1)) with isoflurane
Number of subjects: 100
Study 9728851 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (effect site target of 50 ng/mL) with isoflurane
Number of subjects: 100
Study 9728851 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil with small-dose esmolol (50 microg x kg(‐1) x min(‐1))
Number of subjects: 100
Study 9728851 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil with large-dose esmolol
Number of subjects: 100
Study 9728851 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol and alfentanil
Number of subjects: 100
Study 9419752 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen patch (TE2)
Number of subjects: 14
Study 9419752 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen patch with added medroxyprogesterone acetate (TE2/MPA)
Number of subjects: 14
Study 9419752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2195800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 0
Study 2195800 — intervention group
Group type: COMPARATOR
Intervention: Gentamycin
Number of subjects: 0
Study 55780 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (≤320 mg/day, increased to 960 mg if inadequate response)
Number of subjects: 29
Study 55780 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (≤1 g/day, increased to 3 g if inadequate response)
Number of subjects: 29
Study 55780 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 29
Study 30852482 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg, 1 time/day
Number of subjects: 0
Study 27889459 — intervention group
Group type: EXPERIMENTAL
Intervention: Music by David Tolley
Number of subjects: 138
Study 27889459 — intervention group
Group type: EXPERIMENTAL
Intervention: Music by Kevin Kern
Number of subjects: 138
Study 27889459 — intervention group
Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 138
Study 26199710 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered IV midazolam (0.5 mg/kg for children under 5 years, 0.2 mg/kg for patients over 5 years)
Number of subjects: 88
Study 26199710 — intervention group
Group type: COMPARATOR
Intervention: Commercially prepared midazolam syrup
Number of subjects: 88
Study 26199710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IV/Oral and syrup)
Number of subjects: 88
Study 23604057 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic repair
Number of subjects: 20
Study 23604057 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 20
Study 23604057 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic repair for CDH
Number of subjects: 20
Study 23604057 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic repair for EA/TEF
Number of subjects: 20
Study 16548949 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O introduced after baseline blood gas measurements
Number of subjects: 20
Study 16548949 — intervention group
Group type: COMPARATOR
Intervention: Control group continued breathing F(I O2) in nitrogen (N2)
Number of subjects: 20
Study 12632292 — intervention group
Group type: EXPERIMENTAL
Intervention: Miflonide (Budesonide 400 ‐ 800 microg per day) and Foradil (Formoterol 24 ‐ 48 microg per day)
Number of subjects: 80
Study 12632292 — intervention group
Group type: EXPERIMENTAL
Intervention: Miflonide/Foradil
Number of subjects: 80
Study 10583852 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin (15 pmol kg‐1 h‐1)
Number of subjects: 10
Study 10583852 — intervention group
Group type: COMPARATOR
Intervention: Gastrin (15 pmol kg‐1 h‐1) with omeprazole pretreatment
Number of subjects: 10
Study 10583852 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 8902042 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to produce the sign language equivalent of each stimulus word
Number of subjects: 44
Study 8902042 — intervention group
Group type: COMPARATOR
Intervention: Instructions to fingerspell each word
Number of subjects: 44
Study 8902042 — intervention group
Group type: COMPARATOR
Intervention: Instructions to form a sign language sentence that included the stimulus word
Number of subjects: 44
Study 8902042 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus words rated high in imagery value
Number of subjects: 44
Study 8902042 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate recall of words
Number of subjects: 44
Study 8902042 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed final recall
Number of subjects: 44
Study 1794157 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous or unequal day-night terbutaline dosing (initial bolus doses of 1.47, 2.94, and 4.41 micrograms/kg)
Number of subjects: 45
Study 1794157 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 45
Study 6336954 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 64
Study 6336954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 29660034 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes (Arm 1)
Number of subjects: 210
Study 29660034 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo e-cigarettes (Arm 2)
Number of subjects: 210
Study 29660034 — intervention group
Group type: COMPARATOR
Intervention: Control (Arm 3)
Number of subjects: 210
Study 28709452 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented interaction group
Number of subjects: 88
Study 28709452 — intervention group
Group type: COMPARATOR
Intervention: Limited interaction group
Number of subjects: 88
Study 28709452 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (augmented and limited interaction)
Number of subjects: 88
Study 25598314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (TYR)
Number of subjects: 22
Study 25598314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 22465743 — intervention group
Group type: EXPERIMENTAL
Intervention: Left prefrontal TMS at 120% of resting motor threshold
Number of subjects: 185
Study 22465743 — intervention group
Group type: EXPERIMENTAL
Intervention: Left prefrontal TMS with adjustments (1 cm forward)
Number of subjects: 185
Study 21576052 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovac Quick‐Draw device
Number of subjects: 278
Study 21576052 — intervention group
Group type: COMPARATOR
Intervention: Traditional capillary blood draws
Number of subjects: 278
Study 18996742 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem (10mg)
Number of subjects: 18
Study 18996742 — intervention group
Group type: COMPARATOR
Intervention: Oral zolpidem (10mg)
Number of subjects: 18
Study 16999754 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative autologous blood re-infusion system 1
Number of subjects: 70
Study 16999754 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative autologous blood re-infusion system 2
Number of subjects: 70
Study 16999754 — intervention group
Group type: COMPARATOR
Intervention: Control group (no re-infusion)
Number of subjects: 70
Study 14532838 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (TCl) 10, 15, 20, or 25 mg daily for 21 days
Number of subjects: 58
Study 14532838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 14532838 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (TCl)
Number of subjects: 58
Study 10897047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen of doxorubicin and CMF
Number of subjects: 403
Study 10897047 — intervention group
Group type: COMPARATOR
Intervention: Alternating regimen of doxorubicin and CMF
Number of subjects: 403
Study 10897047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 403
Study 10897047 — intervention group
Group type: EXPERIMENTAL
Intervention: High TLI
Number of subjects: 403
Study 8782125 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hyaluronic acid (HA) measurement
Number of subjects: 65
Study 8782125 — intervention group
Group type: COMPARATOR
Intervention: Erythrocyte sedimentation rate (ESR)
Number of subjects: 65
Study 8782125 — intervention group
Group type: COMPARATOR
Intervention: C reactive protein (CRP)
Number of subjects: 65
Study 1281727 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 132
Study 1281727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 6378743 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ISDN (isosorbide dinitrate) acute administration
Number of subjects: 10
Study 6378743 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ISDN (isosorbide dinitrate) during long-term treatment
Number of subjects: 10
Study 6378743 — intervention group
Group type: COMPARATOR
Intervention: Control values during long-term treatment
Number of subjects: 10
Study 29575708 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training with vascular occlusion (n = 15)
Number of subjects: 30
Study 29575708 — intervention group
Group type: COMPARATOR
Intervention: Control exercise group (n = 15)
Number of subjects: 30
Study 26453367 — intervention group
Group type: EXPERIMENTAL
Intervention: LA Sprouts (nutrition, cooking, and gardening intervention)
Number of subjects: 304
Study 26453367 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study 24597620 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 25 mg, 75 mg, 150 mg, 300 mg
Number of subjects: 237
Study 24597620 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (all dose groups combined)
Number of subjects: 237
Study 24597620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 22994224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive level of glucose control
Number of subjects: 0
Study 22994224 — intervention group
Group type: COMPARATOR
Intervention: Standard of care glucose control
Number of subjects: 0
Study 20068568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 400 mg/m² at first infusion followed by weekly infusions of 250 mg/m² combined with FUFOX (oxaliplatin 50 mg/m², 5-FU 2000 mg/m², and DL-folinic acid 200 mg/m²)
Number of subjects: 52
Study 20068568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FUFOX
Number of subjects: 52
Study 17331807 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider education
Number of subjects: 0
Study 17331807 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 0
Study 17331807 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider/patient education
Number of subjects: 0
Study 17331807 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15826417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 20 mg/kg on induction
Number of subjects: 64
Study 15826417 — intervention group
Group type: COMPARATOR
Intervention: No tranexamic acid
Number of subjects: 64
Study 12160267 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of laryngoscopic findings associated with LPRD
Number of subjects: 120
Study 10197834 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 20
Study 10197834 — intervention group
Group type: COMPARATOR
Intervention: Healthy control men
Number of subjects: 20
Study 7750382 — intervention group
Group type: EXPERIMENTAL
Intervention: Form-function correspondences
Number of subjects: 2
Study 7750382 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual similarity motivated by intuitive beliefs about correspondences between form and function
Number of subjects: 2
Study 2405107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) plus Cisplatin (CDDP)
Number of subjects: 122
Study 2405107 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (FU) alone
Number of subjects: 122
Study 6253122 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (2 mg day‐1 kg‐1) given orally for 7 days
Number of subjects: 0
Study 31902875 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg administered intravenously four times with an inter-dose interval of 2 weeks)
Number of subjects: 10
Study 31779678 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with DMP
Number of subjects: 339
Study 31779678 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with DMP plus M-POWER Rewards
Number of subjects: 339
Study 31779678 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 339
Study 29960291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spondylosis formula granules
Number of subjects: 499
Study 29960291 — intervention group
Group type: COMPARATOR
Intervention: Jingfukang granules
Number of subjects: 499
Study 25845867 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg KAE609 plus 320 mg PPQ
Number of subjects: 110
Study 25845867 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg KAE609 plus 1,280 mg PPQ
Number of subjects: 110
Study 25845867 — intervention group
Group type: COMPARATOR
Intervention: PPQ alone (320 mg)
Number of subjects: 110
Study 25845867 — intervention group
Group type: COMPARATOR
Intervention: KAE609 alone (25 mg)
Number of subjects: 110
Study 25845867 — intervention group
Group type: EXPERIMENTAL
Intervention: KAE609 and PPQ combination
Number of subjects: 110
Study 23750459 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I (1 week) + iCBT (10 weeks)
Number of subjects: 69
Study 23750459 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I + iCBT
Number of subjects: 69
Study 23750459 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 69
Study 20963449 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (titrated from 50 mg to 100 mg 3 times daily)
Number of subjects: 105
Study 20963449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 19276198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 6 mg of nicorandil
Number of subjects: 408
Study 19276198 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 408
Study 17113349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg/day)
Number of subjects: 40
Study 17113349 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg/day)
Number of subjects: 40
Study 17113349 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ramipril and telmisartan
Number of subjects: 40
Study 15017470 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended interval dosing (EID) of gentamicin
Number of subjects: 40
Study 15017470 — intervention group
Group type: COMPARATOR
Intervention: Conventional interval dosing (CID) of gentamicin
Number of subjects: 40
Study 11199955 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine administered concomitantly with phenytoin
Number of subjects: 0